FGF2 Binding, Signaling, and Angiogenesis Are Modulated by Heparanase in Metastatic Melanoma Cells

Overview

Journal Neoplasia

Publisher Elsevier

Specialty Oncology

Date 2006 Jul 27

PMID 16867222

Citations 37

Authors

Jane Reiland

Doty Kempf

Madhuchhanda Roy

Yvonne Denkins

Dario Marchetti

Affiliations

Soon will be listed here.

Abstract

Heparanase (HPSE) and fibroblast growth factor-2 (FGF2) are critical regulators of melanoma angiogenesis and metastasis. Elevated HPSE expression contributes to melanoma progression; however, further augmentation of HPSE presence can inhibit tumorigenicity. HPSE enzymatically cleaves heparan sulfate glycosaminoglycan chains (HS) from proteoglycans. HS act as both low-affinity FGF2 receptors and coreceptors in the formation of high-affinity FGF2 receptors. We have investigated HPSE's ability to modulate FGF2 activity through HS remodeling. Extensive HPSE degradation of human metastatic melanoma cells (70W) inhibited FGF2 binding. Unexpectedly, treatment of 70W cells with low HPSE concentrations enhanced FGF2 binding. In addition, HPSE-unexposed cells did not phosphorylate extracellular signal-related kinase (ERK) or focal adhesion kinase (FAK) in response to FGF2. Conversely, in cells treated with HPSE, FGF2 stimulated ERK and FAK phosphorylation. Secondly, the presence of soluble HPSE-degraded HS enhanced FGF2 binding and ERK phosphorylation at low HS concentrations. Higher concentrations of soluble HS inhibited FGF2 binding, but FGF2 signaling through ERK remained enhanced. Soluble HS were unable to support FGF2-stimulated FAK phosphorylation irrespective of HPSE treatment. Finally, cell exposure to HPSE or to HPSE-degraded HS modulated FGF2-induced angiogenesis in melanoma. In conclusion, these effects suggest relevant mechanisms for the HPSE modulation of melanoma growth factor responsiveness and tumorigenicity.

Citing Articles

Melanoma-derived extracellular vesicles transfer proangiogenic factors.

Wilczak M, Surman M, PRZYBYlO M Oncol Res. 2025; 33(2):245-262.

PMID: 39866233 PMC: 11753996. DOI: 10.32604/or.2024.055449.

LGALS3BP is a novel and potential biomarker in clear cell renal cell carcinoma.

Li L, Qin S, Tan H, Zhou J Aging (Albany NY). 2024; 16(4):4033-4051.

PMID: 38393692 PMC: 10929836. DOI: 10.18632/aging.205578.

Heparanase-1: From Cancer Biology to a Future Antiviral Target.

Lebsir N, Zoulim F, Grigorov B Viruses. 2023; 15(1).

PMID: 36680276 PMC: 9860851. DOI: 10.3390/v15010237.

Harnessing Extracellular Matrix Biology for Tumor Drug Delivery.

Subrahmanyam N, Ghandehari H J Pers Med. 2021; 11(2).

PMID: 33572559 PMC: 7911184. DOI: 10.3390/jpm11020088.

Perlecan in the Natural and Cell Therapy Repair of Human Adult Articular Cartilage: Can Modifications in This Proteoglycan Be a Novel Therapeutic Approach?.

Garcia J, McCarthy H, Kuiper J, Melrose J, Roberts S Biomolecules. 2021; 11(1).

PMID: 33450893 PMC: 7828356. DOI: 10.3390/biom11010092.

References

Iozzo R . Heparan sulfate proteoglycans: intricate molecules with intriguing functions. J Clin Invest. 2001; 108(2):165-7. PMC: 203034. DOI: 10.1172/JCI13560. View

Rapraeger A, Krufka A, Olwin B . Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. Science. 1991; 252(5013):1705-8. DOI: 10.1126/science.1646484. View

Berry D, Shriver Z, Natke B, Kwan C, Venkataraman G, Sasisekharan R . Heparan sulphate glycosaminoglycans derived from endothelial cells and smooth muscle cells differentially modulate fibroblast growth factor-2 biological activity through fibroblast growth factor receptor-1. Biochem J. 2003; 373(Pt 1):241-9. PMC: 1223466. DOI: 10.1042/BJ20021760. View

Roy M, Reiland J, Murry B, Chouljenko V, Kousoulas K, Marchetti D . Antisense-mediated suppression of Heparanase gene inhibits melanoma cell invasion. Neoplasia. 2005; 7(3):253-62. PMC: 1501137. DOI: 10.1593/neo.04493. View

Gong F, Jemth P, Escobar Galvis M, Vlodavsky I, Horner A, Lindahl U . Processing of macromolecular heparin by heparanase. J Biol Chem. 2003; 278(37):35152-8. DOI: 10.1074/jbc.M300925200. View

Okada Y, Yamada S, Toyoshima M, Dong J, Nakajima M, Sugahara K . Structural recognition by recombinant human heparanase that plays critical roles in tumor metastasis. Hierarchical sulfate groups with different effects and the essential target disulfated trisaccharide sequence. J Biol Chem. 2002; 277(45):42488-95. DOI: 10.1074/jbc.M206510200. View

Abdel-Ghany M, Cheng H, Elble R, Pauli B . Focal adhesion kinase activated by beta(4) integrin ligation to mCLCA1 mediates early metastatic growth. J Biol Chem. 2002; 277(37):34391-400. DOI: 10.1074/jbc.M205307200. View

Sanderson R . Heparan sulfate proteoglycans in invasion and metastasis. Semin Cell Dev Biol. 2001; 12(2):89-98. DOI: 10.1006/scdb.2000.0241. View

Hunger-Glaser I, Fan R, Perez-Salazar E, Rozengurt E . PDGF and FGF induce focal adhesion kinase (FAK) phosphorylation at Ser-910: dissociation from Tyr-397 phosphorylation and requirement for ERK activation. J Cell Physiol. 2004; 200(2):213-22. DOI: 10.1002/jcp.20018. View

10.

Yang Y, Borset M, Langford J, Sanderson R . Heparan sulfate regulates targeting of syndecan-1 to a functional domain on the cell surface. J Biol Chem. 2003; 278(15):12888-93. DOI: 10.1074/jbc.M209440200. View

11.

Liu D, Shriver Z, Venkataraman G, El Shabrawi Y, Sasisekharan R . Tumor cell surface heparan sulfate as cryptic promoters or inhibitors of tumor growth and metastasis. Proc Natl Acad Sci U S A. 2002; 99(2):568-73. PMC: 117346. DOI: 10.1073/pnas.012578299. View

12.

Powell A, Yates E, Fernig D, Turnbull J . Interactions of heparin/heparan sulfate with proteins: appraisal of structural factors and experimental approaches. Glycobiology. 2004; 14(4):17R-30R. DOI: 10.1093/glycob/cwh051. View

13.

Nurcombe V, Smart C, Chipperfield H, Cool S, Boilly B, Hondermarck H . The proliferative and migratory activities of breast cancer cells can be differentially regulated by heparan sulfates. J Biol Chem. 2000; 275(39):30009-18. DOI: 10.1074/jbc.M003038200. View

14.

Rahmoune H, Chen H, Gallagher J, Rudland P, Fernig D . Interaction of heparan sulfate from mammary cells with acidic fibroblast growth factor (FGF) and basic FGF. Regulation of the activity of basic FGF by high and low affinity binding sites in heparan sulfate. J Biol Chem. 1998; 273(13):7303-10. DOI: 10.1074/jbc.273.13.7303. View

15.

Vlodavsky I, Friedmann Y . Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest. 2001; 108(3):341-7. PMC: 209369. DOI: 10.1172/JCI13662. View

16.

Kreuger J, Salmivirta M, Sturiale L, Gimenez-Gallego G, Lindahl U . Sequence analysis of heparan sulfate epitopes with graded affinities for fibroblast growth factors 1 and 2. J Biol Chem. 2001; 276(33):30744-52. DOI: 10.1074/jbc.M102628200. View

17.

Ibrahimi O, Yeh B, Eliseenkova A, Zhang F, Olsen S, Igarashi M . Analysis of mutations in fibroblast growth factor (FGF) and a pathogenic mutation in FGF receptor (FGFR) provides direct evidence for the symmetric two-end model for FGFR dimerization. Mol Cell Biol. 2005; 25(2):671-84. PMC: 543411. DOI: 10.1128/MCB.25.2.671-684.2005. View

18.

Smalley K . A pivotal role for ERK in the oncogenic behaviour of malignant melanoma?. Int J Cancer. 2003; 104(5):527-32. DOI: 10.1002/ijc.10978. View

19.

Newman D, Li C, Simmons R, Khosla J, Sannes P . Heparin affects signaling pathways stimulated by fibroblast growth factor-1 and -2 in type II cells. Am J Physiol Lung Cell Mol Physiol. 2004; 287(1):L191-200. DOI: 10.1152/ajplung.00284.2003. View

20.

Lazar-Molnar E, Hegyesi H, Toth S, Falus A . Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine. 2000; 12(6):547-54. DOI: 10.1006/cyto.1999.0614. View